Targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors for developing effective antipsychotics: Synthesis, biological characterization, and behavioral studies

Journal of Medicinal Chemistry

Volumn 57, Issue 22, 2014, Pages 9578-9597

  Brindisi, Margherita ^a   Butini, Stefania ^a   Franceschini, Silvia ^a   Brogi, Simone ^a   Trotta, Francesco ^a   Ros, Sindu ^a   Cagnotto, Alfredo ^b   Salmona, Mario ^b   Casagni, Alice ^a   Andreassi, Marco ^a   Saponara, Simona ^a   Gorelli, Beatrice ^a   Weikop, Pia ^c   Mikkelsen, Jens D ^d   Scheel Kruger, Jorgen ^e   Sandager Nielsen, Karin ^e,g   Novellino, Ettore ^a,f   Campiani, Giuseppe ^a   Gemma, Sandra ^a  

^a UNIVERSITY OF SIENA   (Italy)

^b MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d University of Copenhagen   (Denmark)

^e NEUROSEARCH A S   (Denmark)

^f UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^g Saniona A S   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZAMIDE; CLOZAPINE; DIZOCILPINE; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR; HALOPERIDOL; MESORIDAZINE; METHAMPHETAMINE; N (4 (4 (3 METHYLPHENYL)PIPERAZIN 1 YL)BUTYL)ISOQUINOLINE 3 CARBOXAMIDE; N (4 (4 PHENYLPIPERAZIN 1 YL)BUTYL)ISOQUINOLINE 3 CARBOXAMIDE; N (4 (4 PHENYLPIPERAZIN 1 YL)BUTYL)QUINOLINE 6 CARBOXAMIDE; N (4 (4 PHENYLPIPERAZIN1 YL)BUTYL)BENZO[B]FURAN 2 CARBOXAMIDE; N [4 [4 (3 METHOXYPHENYL)PIPERAZIN 1 YL]BUTYL]ISOQUINOLINE 3 CARBOXAMIDE; OLANZAPINE; PIMOZIDE; QUINALDIC ACID; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN RECEPTOR; THIORIDAZINE; UNCLASSIFIED DRUG; AMIDE; DIZOCILPINE MALEATE; DOPAMINE RECEPTOR BLOCKING AGENT; LIGAND; NEUROLEPTIC AGENT; PROTEIN BINDING; SEROTONIN AGONIST;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; BROMINATION; CATALEPSY; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFICACY; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; HYDROGENATION; HYDROXYLATION; HYPERACTIVITY; IN VIVO STUDY; LEARNING DISORDER; LOCOMOTION; MAINTENANCE THERAPY; MICRODIALYSIS; MONOAMINERGIC SYSTEM; MOUSE; NEGATIVE SYNDROME; NONHUMAN; NUCLEUS ACCUMBENS; ONCOGENE C FOS; PARTIAL AGONISM; PASSIVE AVOIDANCE; PREFRONTAL CORTEX; RECEPTOR BINDING; SCHIZOPHRENIA; SEDATION; SEROTONINERGIC SYSTEM; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; TREMOR; ANIMAL; ANIMAL BEHAVIOR; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; KINETICS; MALE; RAT; SPRAGUE DAWLEY RAT;

AMIDES; ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; DIZOCILPINE MALEATE; DOPAMINE ANTAGONISTS; DRUG EVALUATION, PRECLINICAL; FEMALE; KINETICS; LIGANDS; MALE; MICE; PREFRONTAL CORTEX; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D3; SCHIZOPHRENIA; SEROTONIN RECEPTOR AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84913554344     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm501119j     Document Type: Article

References (50)

1. Insel, T. R. Rethinking schizophrenia Nature 2010, 468, 187-193
2. Davis, K. L.; Kahn, R. S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: a review and reconceptualization Am. J. Psychiatry 1991, 148, 1474-1486
3. Seeman, P. Dopamine receptor sequences. Therapeutic levels of neuroleptics occupy D2 receptors, clozapine occupies D4 Neuropsychopharmacology 1992, 7, 261-284
4. Miyamoto, S.; Miyake, N.; Jarskog, L. F.; Fleischhacker, W. W.; Lieberman, J. A. Pharmacological treatment of schizophrenia: a critical review of the pharmacology and clinical effects of current and future therapeutic agents Mol. Psychiatry 2012, 17, 1206-1227
5. Campbell, M.; Young, P. I.; Bateman, D. N.; Smith, J. M.; Thomas, S. H. The use of atypical antipsychotics in the management of schizophrenia Br. J. Clin. Pharmacol. 1999, 47, 13-22
6. Lieberman, J. A.; Stroup, T. S.; McEvoy, J. P.; Swartz, M. S.; Rosenheck, R. A.; Perkins, D. O.; Keefe, R. S.; Davis, S. M.; Davis, C. E.; Lebowitz, B. D.; Severe, J.; Hsiao, J. K. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia N. Engl. J. Med. 2005, 353, 1209-1223
7. Leucht, S.; Corves, C.; Arbter, D.; Engel, R. R.; Li, C.; Davis, J. M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis Lancet 2009, 373, 31-41
8. Buckley, P. F. Aripiprazole: efficacy and tolerability profile of a novel-acting atypical antipsychotic Drugs Today 2003, 39, 145-151
9. Shapiro, D. A.; Renock, S.; Arrington, E.; Chiodo, L. A.; Liu, L. X.; Sibley, D. R.; Roth, B. L.; Mailman, R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology Neuropsychopharmacology 2003, 28, 1400-1411
10. Buchanan, R. W.; Kreyenbuhl, J.; Kelly, D. L.; Noel, J. M.; Boggs, D. L.; Fischer, B. A.; Himelhoch, S.; Fang, B.; Peterson, E.; Aquino, P. R.; Keller, W. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements Schizophr. Bull. 2010, 36, 71-93
11. Miyake, N.; Miyamoto, S.; Jarskog, L. F. New serotonin/dopamine antagonists for the treatment of schizophrenia: are we making real progress? Clin. Schizophr. Relat. Psychoses 2012, 6, 122-133
12. Glassman, A. H.; Bigger, J. T., Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death Am. J. Psychiatry 2001, 158, 1774-1782
13. Ray, W. A.; Chung, C. P.; Murray, K. T.; Hall, K.; Stein, C. M. Atypical antipsychotic drugs and the risk of sudden cardiac death N. Engl. J. Med. 2009, 360, 225-235
14. Millan, M. J.; Fone, K.; Steckler, T.; Horan, W. P. Negative symptoms of schizophrenia: clinical characteristics, pathophysiological substrates, experimental models and prospects for improved treatment Eur. Neuropsychopharmacol. 2014, 24, 645-692
15. Butini, S.; Gemma, S.; Campiani, G.; Franceschini, S.; Trotta, F.; Borriello, M.; Ceres, N.; Ros, S.; Coccone, S. S.; Bernetti, M.; De Angelis, M.; Brindisi, M.; Nacci, V.; Fiorini, I.; Novellino, E.; Cagnotto, A.; Mennini, T.; Sandager-Nielsen, K.; Andreasen, J. T.; Scheel-Kruger, J.; Mikkelsen, J. D.; Fattorusso, C. Discovery of a new class of potential multifunctional atypical antipsychotic agents targeting dopamine D3 and serotonin 5-HT1A and 5-HT2A receptors: design, synthesis, and effects on behavior J. Med. Chem. 2009, 52, 151-169
16. Campiani, G.; Butini, S.; Gemma, S.; Nacci, V.; Fattorusso, C.; Catalanotti, B.; Giorgi, G.; Cagnotto, A.; Goegan, M.; Mennini, T.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies J. Med. Chem. 2002, 45, 344-359
17. Campiani, G.; Butini, S.; Fattorusso, C.; Catalanotti, B.; Gemma, S.; Nacci, V.; Morelli, E.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Carli, M.; Minetti, P.; Di Cesare, M. A.; Mastroianni, D.; Scafetta, N.; Galletti, B.; Stasi, M. A.; Castorina, M.; Pacifici, L.; Vertechy, M.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P. Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents J. Med. Chem. 2004, 47, 143-157
18. Campiani, G.; Butini, S.; Fattorusso, C.; Trotta, F.; Gemma, S.; Catalanotti, B.; Nacci, V.; Fiorini, I.; Cagnotto, A.; Mereghetti, I.; Mennini, T.; Minetti, P.; Di Cesare, M. A.; Stasi, M. A.; Di Serio, S.; Ghirardi, O.; Tinti, O.; Carminati, P. Novel atypical antipsychotic agents: rational design, an efficient palladium-catalyzed route, and pharmacological studies J. Med. Chem. 2005, 48, 1705-1708
19. Campiani, G.; Butini, S.; Trotta, F.; Fattorusso, C.; Catalanotti, B.; Aiello, F.; Gemma, S.; Nacci, V.; Novellino, E.; Stark, J. A.; Cagnotto, A.; Fumagalli, E.; Carnovali, F.; Cervo, L.; Mennini, T. Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors J. Med. Chem. 2003, 46, 3822-3839
20. Butini, S.; Campiani, G.; Franceschini, S.; Trotta, F.; Kumar, V.; Guarino, E.; Borrelli, G.; Fiorini, I.; Novellino, E.; Fattorusso, C.; Persico, M.; Orteca, N.; Sandager-Nielsen, K.; Jacobsen, T. A.; Madsen, K.; Scheel-Kruger, J.; Gemma, S. Discovery of bishomo(hetero)arylpiperazines as novel multifunctional ligands targeting dopamine D(3) and serotonin 5-HT(1A) and 5-HT(2A) receptors J. Med. Chem. 2010, 53, 4803-4807
21. Nagata, R.; Tanno, N.; Kodo, T.; Ae, N.; Yamaguchi, H.; Nishimura, T.; Antoku, F.; Tatsuno, T.; Kato, T.; Tanaka, Y.; Nakamura, M. Tricyclic quinoxalinediones: 5,6-dihydro-1 H -pyrrolo[1,2,3- de ] quinoxaline-2,3-diones and 6,7-dihydro-1 H,5 H -pyrido[1,2,3- de ] quinoxaline-2,3-diones as potent antagonists for the glycine binding site of the NMDA receptor J. Med. Chem. 1994, 37, 3956-3968
22. Katayama, S.; Ae, N.; Nagata, R. Enzymatic resolution of 2-substituted tetrahydroquinolines. Convenient approaches to tricyclic quinoxalinediones as potent NMDA-glycine antagonists Tetrahedron: Asymmetry 1998, 9, 4295-4299
23. Chen, J.; Ding, K.; Levant, B.; Wang, S. Design of novel hexahydropyrazinoquinolines as potent and selective dopamine D3 receptor ligands with improved solubility Bioorg. Med. Chem. Lett. 2006, 16, 443-446
24. Grundt, P.; Carlson, E. E.; Cao, J.; Bennett, C. J.; McElveen, E.; Taylor, M.; Luedtke, R. R.; Newman, A. H. Novel heterocyclic trans olefin analogues of N -{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl}arylcarboxamides as selective probes with high affinity for the dopamine D3 receptor J. Med. Chem. 2005, 48, 839-848
25. Reavill, C.; Taylor, S. G.; Wood, M. D.; Ashmeade, T.; Austin, N. E.; Avenell, K. Y.; Boyfield, I.; Branch, C. L.; Cilia, J.; Coldwell, M. C.; Hadley, M. S.; Hunter, A. J.; Jeffrey, P.; Jewitt, F.; Johnson, C. N.; Jones, D. N.; Medhurst, A. D.; Middlemiss, D. N.; Nash, D. J.; Riley, G. J.; Routledge, C.; Stemp, G.; Thewlis, K. M.; Trail, B.; Vong, A. K.; Hagan, J. J. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A J. Pharmacol. Exp. Ther. 2000, 294, 1154-1165
26. Manzanedo, C.; Aguilar, M. A.; Minarro, J. The effects of dopamine D2 and D3 antagonists on spontaneous motor activity and morphine-induced hyperactivity in male mice Psychopharmacology 1999, 143, 82-88
27. Javitt, D. C.; Zukin, S. R. Recent advances in the phencyclidine model of schizophrenia Am. J. Psychiatry 1991, 148, 1301-1308
28. Lahti, A. C.; Weiler, M. A.; Tamara Michaelidis, B. A.; Parwani, A.; Tamminga, C. A. Effects of ketamine in normal and schizophrenic volunteers Neuropsychopharmacology 2001, 25, 455-467
29. Murase, S.; Mathe, J. M.; Grenhoff, J.; Svensson, T. H. Effects of dizocilpine (MK-801) on rat midbrain dopamine cell activity: differential actions on firing pattern related to anatomical localization J. Neural. Transm.: Gen. Sect. 1993, 91, 13-25
30. Leriche, L.; Schwartz, J. C.; Sokoloff, P. The dopamine D3 receptor mediates locomotor hyperactivity induced by NMDA receptor blockade Neuropharmacology 2003, 45, 174-181
31. Waters, N.; Svensson, K.; Haadsma-Svensson, S. R.; Smith, M. W.; Carlsson, A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity J. Neural. Transm.: Gen. Sect. 1993, 94, 11-19
32. Sautel, F.; Griffon, N.; Sokoloff, P.; Schwartz, J. C.; Launay, C.; Simon, P.; Costentin, J.; Schoenfelder, A.; Garrido, F.; Mann, A. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents J. Pharmacol. Exp. Ther. 1995, 275, 1239-1246
33. Watson, D. J.; Marsden, C. A.; Millan, M. J.; Fone, K. C. Blockade of dopamine D(3) but not D(2) receptors reverses the novel object discrimination impairment produced by post-weaning social isolation: implications for schizophrenia and its treatment Int. J. Neuropsychopharmacol. 2012, 15, 471-484
34. Hancox, J. C.; McPate, M. J.; El Harchi, A.; Zhang, Y. H. The hERG potassium channel and hERG screening for drug-induced torsades de pointes Pharmacol. Ther. 2008, 119, 118-132
35. Gemma, S.; Camodeca, C.; Sanna Coccone, S.; Joshi, B. P.; Bernetti, M.; Moretti, V.; Brogi, S.; Bonache de Marcos, M. C.; Savini, L.; Taramelli, D.; Basilico, N.; Parapini, S.; Rottmann, M.; Brun, R.; Lamponi, S.; Caccia, S.; Guiso, G.; Summers, R. L.; Martin, R. E.; Saponara, S.; Gorelli, B.; Novellino, E.; Campiani, G.; Butini, S. Optimization of 4-aminoquinoline/clotrimazole-based hybrid antimalarials: further structure-activity relationships, in vivo studies, and preliminary toxicity profiling J. Med. Chem. 2012, 55, 6948-6967
36. Deutch, A. Y.; Lee, M. C.; Iadarola, M. J. Regionally specific effects of atypical antipsychotic drugs on striatal Fos expression: The nucleus accumbens shell as a locus of antipsychotic action Mol. Cell. Neurosci. 1992, 3, 332-341
37. Robertson, G. S.; Fibiger, H. C. Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine Neuroscience 1992, 46, 315-328
38. Tremblay, P. O.; Gervais, J.; Rouillard, C. Modification of haloperidol-induced pattern of c-fos expression by serotonin agonists Eur. J. Neurosci. 1998, 10, 3546-3555
39. Vianna, M. R.; Izquierdo, L. A.; Barros, D. M.; Ardenghi, P.; Pereira, P.; Rodrigues, C.; Moletta, B.; Medina, J. H.; Izquierdo, I. Differential role of hippocampal cAMP-dependent protein kinase in short- and long-term memory Neurochem. Res. 2000, 25, 621-626
40. Braff, D. L.; Geyer, M. A.; Swerdlow, N. R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies Psychopharmacology 2001, 156, 234-258
41. Park, W. K.; Jeong, D.; Cho, H.; Lee, S. J.; Cha, M. Y.; Pae, A. N.; Choi, K. I.; Koh, H. Y.; Kong, J. Y. KKHA-761, a potent D3 receptor antagonist with high 5-HT1A receptor affinity, exhibits antipsychotic properties in animal models of schizophrenia Pharmacol., Biochem. Behav. 2005, 82, 361-372
42. Sandager-Nielsen, K.; Andersen, M. B.; Sager, T. N.; Werge, T.; Scheel-Kruger, J. Effects of postnatal anoxia on striatal dopamine metabolism and prepulse inhibition in rats Pharmacol., Biochem. Behav. 2004, 77, 767-774
43. Joel, D. Current animal models of obsessive compulsive disorder: a critical review Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30, 374-388
44. Matsushita, M.; Egashira, N.; Harada, S.; Okuno, R.; Mishima, K.; Iwasaki, K.; Nishimura, R.; Fujiwara, M. Perospirone, a novel antipsychotic drug, inhibits marble-burying behavior via 5-HT1A receptor in mice: implications for obsessive-compulsive disorder J. Pharmacol. Sci. 2005, 99, 154-159
45. Egashira, N.; Okuno, R.; Matsushita, M.; Abe, M.; Mishima, K.; Iwasaki, K.; Nishimura, R.; Oishi, R.; Fujiwara, M. Aripiprazole inhibits marble-burying behavior via 5-hydroxytryptamine (5-HT)1A receptor-independent mechanisms Eur. J. Pharmacol. 2008, 592, 103-108
46. Harvey, P. D.; Meltzer, H.; Simpson, G. M.; Potkin, S. G.; Loebel, A.; Siu, C.; Romano, S. J. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia Schizophr. Res. 2004, 66, 101-113
47. Ichikawa, J.; Ishii, H.; Bonaccorso, S.; Fowler, W. L.; O'Laughlin, I. A.; Meltzer, H. Y. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release J. Neurochem. 2001, 76, 1521-1531
48. Saponara, S.; Ferrara, A.; Gorelli, B.; Shah, A.; Kawase, M.; Motohashi, N.; Molnar, J.; Sgaragli, G.; Fusi, F. 3,5-D-4-(3-phenoxyphenyl)-1,4-dihydro-2,6-dimethylpyridine (DP7): a new multidrug resistance inhibitor devoid of effects on Langendorff-perfused rat heart Eur. J. Pharmacol. 2007, 563, 160-163
49. Ferrara, A.; Fusi, F.; Gorelli, B.; Sgaragli, G.; Saponara, S. Effects of freeze-dried red wine on cardiac function and ECG of the Langendorff-perfused rat heart Can. J. Physiol. Pharmacol. 2014, 92, 171-174
50. Weikop, P.; Egestad, B.; Kehr, J. Application of triple-probe microdialysis for fast pharmacokinetic/pharmacodynamic evaluation of dopamimetic activity of drug candidates in the rat brain J. Neurosci. Meth. 2004, 140, 59-65